AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume

AnaptysBio Inc (NASDAQ:ANAB) saw unusually-strong trading volume on Monday . Approximately 1,091,837 shares were traded during mid-day trading, an increase of 151% from the previous session’s volume of 435,734 shares.The stock last traded at $14.24 and had previously closed at $13.49.

A number of research analysts have weighed in on ANAB shares. BidaskClub raised AnaptysBio from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a research note on Wednesday, November 13th. Wedbush lowered shares of AnaptysBio from an “outperform” rating to a “neutral” rating in a report on Friday, November 8th. Credit Suisse Group decreased their target price on shares of AnaptysBio from $75.00 to $48.00 and set a “neutral” rating on the stock in a research report on Thursday, October 3rd. Finally, ValuEngine upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, August 16th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $75.11.

The firm has a market cap of $366.03 million, a price-to-earnings ratio of -5.66 and a beta of 1.12. The business’s 50-day moving average price is $24.79 and its two-hundred day moving average price is $45.94.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Friday, November 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.06). During the same quarter last year, the business earned ($0.66) earnings per share. As a group, sell-side analysts expect that AnaptysBio Inc will post -4.01 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aperio Group LLC acquired a new stake in AnaptysBio in the second quarter worth $45,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of AnaptysBio by 42.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,851 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 553 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in shares of AnaptysBio during the third quarter worth about $66,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of AnaptysBio in the 1st quarter worth about $110,000. Finally, Bank of Montreal Can acquired a new stake in shares of AnaptysBio in the 2nd quarter worth about $115,000.

AnaptysBio Company Profile (NASDAQ:ANAB)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Recommended Story: How is an ETF different from a mutual fund?

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with's FREE daily email newsletter.